NZ596428A - Method of reducing intraocular pressure in humans - Google Patents
Method of reducing intraocular pressure in humansInfo
- Publication number
- NZ596428A NZ596428A NZ596428A NZ59642810A NZ596428A NZ 596428 A NZ596428 A NZ 596428A NZ 596428 A NZ596428 A NZ 596428A NZ 59642810 A NZ59642810 A NZ 59642810A NZ 596428 A NZ596428 A NZ 596428A
- Authority
- NZ
- New Zealand
- Prior art keywords
- intraocular pressure
- humans
- reducing intraocular
- purin
- dihydroxytetrahydrofuran
- Prior art date
Links
- 230000004410 intraocular pressure Effects 0.000 title abstract 2
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- SYHNGKRBPFJKCW-DNBRLMRSSA-M sodium;[(2r,3s,4r,5r)-5-[6-(cyclopentylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl sulfate Chemical compound [Na+].O[C@@H]1[C@H](O)[C@@H](COS([O-])(=O)=O)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 SYHNGKRBPFJKCW-DNBRLMRSSA-M 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Prostheses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17465509P | 2009-05-01 | 2009-05-01 | |
| US21999009P | 2009-06-24 | 2009-06-24 | |
| PCT/US2010/033112 WO2010127210A1 (en) | 2009-05-01 | 2010-04-30 | Method of reducing intraocular pressure in humans |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ596428A true NZ596428A (en) | 2014-03-28 |
Family
ID=43030847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ596428A NZ596428A (en) | 2009-05-01 | 2010-04-30 | Method of reducing intraocular pressure in humans |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8470800B2 (enExample) |
| EP (1) | EP2424546B1 (enExample) |
| JP (1) | JP5778663B2 (enExample) |
| KR (1) | KR101757940B1 (enExample) |
| CN (1) | CN102413832B (enExample) |
| AU (1) | AU2010242943B2 (enExample) |
| BR (1) | BRPI1009971A2 (enExample) |
| CA (1) | CA2762064A1 (enExample) |
| CL (1) | CL2011002675A1 (enExample) |
| DK (1) | DK2424546T3 (enExample) |
| EA (1) | EA024042B1 (enExample) |
| ES (1) | ES2554684T3 (enExample) |
| HR (1) | HRP20151200T1 (enExample) |
| HU (1) | HUE028068T2 (enExample) |
| IL (1) | IL216081A (enExample) |
| MX (1) | MX2011011229A (enExample) |
| MY (1) | MY159244A (enExample) |
| NZ (1) | NZ596428A (enExample) |
| PL (1) | PL2424546T3 (enExample) |
| PT (1) | PT2424546E (enExample) |
| RS (1) | RS54378B1 (enExample) |
| SG (1) | SG175346A1 (enExample) |
| SI (1) | SI2424546T1 (enExample) |
| SM (1) | SMT201500295B (enExample) |
| WO (1) | WO2010127210A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
| DE102009006602A1 (de) * | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
| CN102665730A (zh) * | 2009-10-26 | 2012-09-12 | 伊诺泰克制药公司 | 眼用制剂及其制造方法 |
| BR112012017106A2 (pt) * | 2010-01-11 | 2018-05-29 | Inotek Pharmaceuticals Corp | combinação, kit e método de redução de pressão intraocular. |
| HUE031529T2 (en) * | 2010-03-19 | 2017-07-28 | Inotek Pharmaceuticals Corp | Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure |
| JP2013522323A (ja) * | 2010-03-19 | 2013-06-13 | イノテック ファーマシューティカルズ コーポレイション | 眼内圧を下げるためのアデノシンＡ１受容体アゴニストと非選択的β−アドレナリン受容体遮断薬との組合せ組成物 |
| JP2013523739A (ja) | 2010-03-26 | 2013-06-17 | イノテック ファーマシューティカルズ コーポレイション | Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法 |
| DE102010030688A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dicyanopyridine und ihre Verwendung |
| US20120058983A1 (en) * | 2010-09-02 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension |
| NZ627778A (en) * | 2012-01-26 | 2017-01-27 | Inotek Pharmaceuticals Corp | Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof |
| AU2014239222A1 (en) | 2013-03-15 | 2015-10-01 | Inotek Pharmaceuticals Corporation | Ophthalmic formulations |
| JP2018501219A (ja) * | 2014-12-03 | 2018-01-18 | イノテック ファーマシューティカルズ コーポレイション | 黄斑変性の予防、軽減または治療方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101010085B (zh) * | 2004-05-26 | 2012-12-26 | 伊诺泰克制药公司 | 嘌呤衍生物作为腺苷a1受体激动剂及其用法 |
| PT1758596E (pt) * | 2004-05-26 | 2010-06-23 | Inotek Pharmaceuticals Corp | Derivados de purina como agonistas do receptor de adenosina a1 e processos para a sua utilização |
| AU2006320578B2 (en) * | 2005-11-30 | 2013-01-31 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
| CN102665730A (zh) * | 2009-10-26 | 2012-09-12 | 伊诺泰克制药公司 | 眼用制剂及其制造方法 |
| BR112012017106A2 (pt) * | 2010-01-11 | 2018-05-29 | Inotek Pharmaceuticals Corp | combinação, kit e método de redução de pressão intraocular. |
| HUE031529T2 (en) * | 2010-03-19 | 2017-07-28 | Inotek Pharmaceuticals Corp | Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure |
| JP2013522323A (ja) * | 2010-03-19 | 2013-06-13 | イノテック ファーマシューティカルズ コーポレイション | 眼内圧を下げるためのアデノシンＡ１受容体アゴニストと非選択的β−アドレナリン受容体遮断薬との組合せ組成物 |
-
2010
- 2010-04-30 KR KR1020117025057A patent/KR101757940B1/ko not_active Expired - Fee Related
- 2010-04-30 CA CA2762064A patent/CA2762064A1/en not_active Abandoned
- 2010-04-30 AU AU2010242943A patent/AU2010242943B2/en not_active Ceased
- 2010-04-30 WO PCT/US2010/033112 patent/WO2010127210A1/en not_active Ceased
- 2010-04-30 NZ NZ596428A patent/NZ596428A/en not_active IP Right Cessation
- 2010-04-30 RS RS20150782A patent/RS54378B1/sr unknown
- 2010-04-30 SI SI201031070T patent/SI2424546T1/sl unknown
- 2010-04-30 SG SG2011078151A patent/SG175346A1/en unknown
- 2010-04-30 US US12/771,289 patent/US8470800B2/en not_active Expired - Fee Related
- 2010-04-30 ES ES10770402.5T patent/ES2554684T3/es active Active
- 2010-04-30 JP JP2012508764A patent/JP5778663B2/ja not_active Expired - Fee Related
- 2010-04-30 BR BRPI1009971A patent/BRPI1009971A2/pt not_active IP Right Cessation
- 2010-04-30 MX MX2011011229A patent/MX2011011229A/es unknown
- 2010-04-30 CN CN201080018539.XA patent/CN102413832B/zh not_active Expired - Fee Related
- 2010-04-30 EA EA201171339A patent/EA024042B1/ru not_active IP Right Cessation
- 2010-04-30 HR HRP20151200TT patent/HRP20151200T1/hr unknown
- 2010-04-30 DK DK10770402.5T patent/DK2424546T3/en active
- 2010-04-30 MY MYPI2011004858A patent/MY159244A/en unknown
- 2010-04-30 HU HUE10770402A patent/HUE028068T2/en unknown
- 2010-04-30 PT PT107704025T patent/PT2424546E/pt unknown
- 2010-04-30 PL PL10770402T patent/PL2424546T3/pl unknown
- 2010-04-30 EP EP10770402.5A patent/EP2424546B1/en active Active
-
2011
- 2011-10-27 CL CL2011002675A patent/CL2011002675A1/es unknown
- 2011-11-01 IL IL216081A patent/IL216081A/en not_active IP Right Cessation
-
2013
- 2013-04-03 US US13/855,919 patent/US20130217643A1/en not_active Abandoned
-
2015
- 2015-11-30 SM SM201500295T patent/SMT201500295B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ596428A (en) | Method of reducing intraocular pressure in humans | |
| MY155658A (en) | A-isopropylphenyl glucitol compounds as sglti inhibitors | |
| MX2009009416A (es) | Derivados de bencimidazol y sus metodos de uso. | |
| TW200637839A (en) | 1-thio-d-glucitol derivatives | |
| JO3152B1 (ar) | مشتقات غلايكوسيد و استخداماتها من ذلك | |
| JO2939B1 (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
| PH12014501134A1 (en) | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| NZ707859A (en) | Inhibitors of sodium glucose cotransporter 1 | |
| NZ591315A (en) | 2-oxo-1,2-dihydro-quinoline modulators of immune function | |
| PE20080773A1 (es) | Composicion farmaceutica que comprende bis-(monoetanolamina) de acido 3'-[(2z)-[1-(3,4-dimetilfenil)-1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-ilideno]hidrazino]-2'-hidroxi-[1,1'-bifenil]-3-carboxilico | |
| MY160123A (en) | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof | |
| MX2009001072A (es) | Proceso de sintesis de macrolido. | |
| MX352992B (es) | Prevencion y tratamiento de la enfermedad de nosema en abejas. | |
| BRPI0924653B8 (pt) | composto de ferro-oligossacarídeo, composição e uso de deste composto | |
| UA103500C2 (uk) | Сульфоксимінзаміщені анілінопіримідинові похідні як cdk-інгібітори, їх одержання й застосування як лікарських засобів | |
| UA95103C2 (ru) | Замещенные арилсульфонамиды в качестве противовирусных средств | |
| HK1217295A1 (zh) | 4'-疊氮基，3'-脫氧基-3'-氟取代的核苷衍生物 | |
| NZ630760A (en) | A method of providing ocular neuroprotection | |
| WO2010121675A3 (en) | Thiazolyl-benzimidazoles | |
| IL196469A (en) | History of triazine and their use in the preparation of drugs for the treatment of diseases | |
| MY160383A (en) | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension | |
| MX2009001433A (es) | Nucleosidos para suprimir o reducir el desarrollo de resistencia en terapia citostatica. | |
| MX2007001206A (es) | Metodos para tratar la piel para mejorar el tratamiento terapeutico de la misma. | |
| MXPA06012206A (es) | Composicion farmaceutica ozonizada y metodos. | |
| BRPI0607995B8 (pt) | composto de fórmula (i), método para preparar o composto de fórmula (i) e uso do composto de fórmula (i) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Error or correction |
Free format text: THE AGENT HAS BEEN CORRECTED TO 1357371, IN-LEGAL LIMITED, 2 BUCHANAN STREET, WADESTOWN, WELLINGTON 6012, NZ; THE CONTACT HAS BEEN CORRECTED TO 1357371, IN-LEGAL LIMITED, 2 BUCHANAN STREET, WADESTOWN, WELLINGTON 6012, NZ Effective date: 20140226 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 APR 2017 BY COMPUTER PACKAGES INC Effective date: 20140828 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2018 BY COMPUTER PACKAGES INC Effective date: 20170331 |
|
| LAPS | Patent lapsed |